{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:23:26Z","timestamp":1789118606805,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Inappropriate direct oral anticoagulant (DOAC) prescribing is a frequent cause of harm to patients. Pharmacists could play an important role in optimising prescribing, but they need access to relevant clinical data to do so. Little is known about community pharmacists\u2019 access to clinical data to assess the appropriateness of DOAC prescriptions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate the availability of relevant clinical data for DOAC prescriptions and whether additionally requesting such data supports community pharmacists in assessing and optimising DOAC prescriptions. This study also explored behavioural factors influencing pharmacists\u2019 decisions to request additional clinical data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>In this mixed-methods study, 166 community pharmacies were approached to collect quantitative data. This included the prevalence of missing clinical data, pharmacists\u2019 requests for missing data including reasons for requesting these data, and prescription adjustments made by the pharmacist. Missing clinical data was defined as absence of patient information on the DOAC prescription to assess its appropriateness: treatment indication, renal function, body weight, treatment duration, or concomitant use of antithrombotics. A random sample of 10 participating pharmacies was approached for semi-structured interviews on perceptions whether to request missing clinical data. Quantitative data were analysed descriptively. Interviews were thematically analysed using the Capability, Opportunity, Motivation, Behaviour (COM-B) framework to understand behaviour. Quantitative and qualitative data were triangulated through discussion of the findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We collected quantitative data of 583 DOAC prescriptions in 92 pharmacies and interviewed 11 pharmacists from 10 approached pharmacies. On 92.8% (n\u2009=\u2009541) of DOAC prescriptions clinical data were missing. Additional clinical data (particularly, treatment indication and renal function) were requested in 51.9% (n\u2009=\u2009281), mainly for dose evaluation (39.6% (n\u2009=\u2009231)), leading to 5.0% (n\u2009=\u200914) adjustments of these prescriptions. Pharmacists applied clinical reasoning to determine the need for additional data, with providing optimal patient care as their primary motivation. The main opportunity was collaboration with other healthcare professionals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Using their clinical reasoning competence, pharmacists frequently requested missing clinical data, particularly treatment indication and renal function, to verify DOAC prescriptions and to ensure optimal patient care. Clinical data sharing could be optimised by streamlined collaboration between healthcare professionals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-026-02159-3","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:33:44Z","timestamp":1779442424000},"page":"1871-1883","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Access to clinical data for direct oral anticoagulant prescriptions in community pharmacy and implications for medication optimisation: a mixed-methods study"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6709-1619","authenticated-orcid":false,"given":"Jacqueline G.","family":"van Paassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-4424","authenticated-orcid":false,"given":"Vera H. M.","family":"Deneer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5173-5005","authenticated-orcid":false,"given":"Thomas G. H.","family":"Kempen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4596-0684","authenticated-orcid":false,"given":"Marcel L.","family":"Bouvy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2159_CR1","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45:3314\u2013414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176.","journal-title":"Eur Heart J"},{"key":"2159_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41:543\u2013603. https:\/\/doi.org\/10.1093\/eurheartj\/ehz405.","journal-title":"Eur Heart J"},{"key":"2159_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","volume":"61","author":"SK Kakkos","year":"2021","unstructured":"Kakkos SK, Gohel M, Baekgaard N, et al. European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg. 2021;61:9\u201382. https:\/\/doi.org\/10.1016\/j.ejvs.2020.09.023.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2159_CR4","doi-asserted-by":"publisher","unstructured":"Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021. https:\/\/doi.org\/10.1093\/europace\/euab065.","DOI":"10.1093\/europace\/euab065"},{"key":"2159_CR5","doi-asserted-by":"publisher","unstructured":"Al Rowily A, Jalal Z, Price MJ, et al. Prevalence, contributory factors and severity of medication errors associated with direct-acting oral anticoagulants in adult patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2022;78:623\u201345. https:\/\/doi.org\/10.1007\/s00228-021-03212-y.","DOI":"10.1007\/s00228-021-03212-y"},{"key":"2159_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1136\/heartjnl-2022-321114","volume":"109","author":"V Caso","year":"2023","unstructured":"Caso V, De Groot JR, Fernandez MS, et al. Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis. Heart. 2023;109:178\u201385. https:\/\/doi.org\/10.1136\/heartjnl-2022-321114.","journal-title":"Heart"},{"key":"2159_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.124.035859","author":"GD Barnes","year":"2024","unstructured":"Barnes GD, Chen C, Holleman R, et al. Pharmacist use of a population management dashboard for safe anticoagulant prescribing: evaluation of a nationwide implementation effort. J Am Heart Assoc. 2024. https:\/\/doi.org\/10.1161\/jaha.124.035859.","journal-title":"J Am Heart Assoc"},{"key":"2159_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjopen\/oeac022","volume":"2","author":"J Seelig","year":"2022","unstructured":"Seelig J, Trinks-Roerdink EM, Chu G, et al. Determinants of label non-adherence to non-vitamin K oral anticoagulants in patients with newly diagnosed atrial fibrillation. Eur Heart J Open. 2022;2:1\u20138. https:\/\/doi.org\/10.1093\/ehjopen\/oeac022.","journal-title":"Eur Heart J Open"},{"key":"2159_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.581293","author":"NN Shen","year":"2021","unstructured":"Shen NN, Zhang C, Hang Y, et al. Real-world prevalence of direct oral anticoagulant off-label doses in atrial fibrillation: an epidemiological meta-analysis. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.581293.","journal-title":"Front Pharmacol"},{"key":"2159_CR10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/BCP.14127","volume":"86","author":"J Santos","year":"2020","unstructured":"Santos J, Ant\u00f3nio N, Rocha M, et al. Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review. Br J Clin Pharmacol. 2020;86:533\u201347. https:\/\/doi.org\/10.1111\/BCP.14127.","journal-title":"Br J Clin Pharmacol"},{"key":"2159_CR11","unstructured":"KNMP. Code of pharmacists. KNMP 2025. https:\/\/www.knmp.nl\/beroepsontwikkeling\/code-van-apothekers (accessed 21 March 2026)."},{"key":"2159_CR12","unstructured":"National Health Care Institute. GIP databank - number of users of antithrombotics from 2020\u20132024 n.d. https:\/\/www.gipdatabank.nl\/databank?infotype=g&label=00-totaal&tabel=B_01-basis&geg=gebr&item=B01A (accessed March 26, 2026)."},{"key":"2159_CR13","doi-asserted-by":"publisher","unstructured":"Koolian M, Wiseman D, Mantzanis H, et al. Anticoagulation stewardship: descriptive analysis of a novel approach to appropriate anticoagulant prescription. Res Pract Thromb Haemost. 2022. https:\/\/doi.org\/10.1002\/rth2.12758.","DOI":"10.1002\/rth2.12758"},{"key":"2159_CR14","doi-asserted-by":"publisher","unstructured":"Chow MMY, Chua DJJ, Wong VSY, et al. Drug-related problems associated with direct oral anticoagulants: an observational cross-sectional study of medical record review by pharmacists in a large teaching hospital. Res Pract Thromb Haemost. 2024. https:\/\/doi.org\/10.1016\/j.rpth.2024.102354.","DOI":"10.1016\/j.rpth.2024.102354"},{"key":"2159_CR15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/BCP.15017","volume":"88","author":"S Moudallel","year":"2022","unstructured":"Moudallel S, Cornu P, Dupont A, et al. Determinants for under- and overdosing of direct oral anticoagulants and physicians\u2019 implementation of clinical pharmacists\u2019 recommendations. Br J Clin Pharmacol. 2022;88:753\u201363. https:\/\/doi.org\/10.1111\/BCP.15017.","journal-title":"Br J Clin Pharmacol"},{"key":"2159_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-020-0157-z","author":"M Miyazaki","year":"2020","unstructured":"Miyazaki M, Matsuo K, Uchiyama M, et al. Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study. J Pharm Health Care Sci. 2020. https:\/\/doi.org\/10.1186\/s40780-020-0157-z.","journal-title":"J Pharm Health Care Sci"},{"key":"2159_CR17","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s11096-021-01302-6","volume":"43","author":"H Haque","year":"2021","unstructured":"Haque H, Al Rowily A, Jalal Z, et al. Direct oral anticoagulant-related medication incidents and pharmacists\u2019 interventions in hospital in-patients: evaluation using Reason\u2019s accident causation theory. Int J Clin Pharm. 2021;43:1693\u2013704. https:\/\/doi.org\/10.1007\/s11096-021-01302-6.","journal-title":"Int J Clin Pharm"},{"key":"2159_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-079018","volume":"14","author":"JG Van Paassen","year":"2024","unstructured":"Van Paassen JG, Tan JP, Deneer VHM, et al. Exploring the pharmacists\u2019 role in optimising antithrombotic therapy in primary care: a qualitative study. BMJ Open. 2024;14:e079018. https:\/\/doi.org\/10.1136\/bmjopen-2023-079018.","journal-title":"BMJ Open"},{"key":"2159_CR19","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpo.2021.0226","author":"YM Osasu","year":"2022","unstructured":"Osasu YM, Mitchell C, Cooper R. Use of direct oral anticoagulants in primary care: a qualitative study integrating patient and practitioner perspectives. BJGP Open. 2022. https:\/\/doi.org\/10.3399\/bjgpo.2021.0226.","journal-title":"BJGP Open"},{"key":"2159_CR20","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s11096-022-01448-x","volume":"44","author":"A Al Rowily","year":"2022","unstructured":"Al Rowily A, Aloudah N, Jalal Z, et al. Views, experiences and contributory factors related to medication errors associated with direct oral anticoagulants: a qualitative study with physicians and nurses. Int J Clin Pharm. 2022;44:1057\u201366. https:\/\/doi.org\/10.1007\/s11096-022-01448-x.","journal-title":"Int J Clin Pharm"},{"key":"2159_CR21","doi-asserted-by":"publisher","unstructured":"Al Rowily A, Aloudah N, Jalal Z, et al. Medication errors in relation to direct-acting oral anticoagulants: a qualitative study of pharmacists\u2019 views and experiences. Int J Clin Pharm. 2023. https:\/\/doi.org\/10.1007\/s11096-023-01555-3.","DOI":"10.1007\/s11096-023-01555-3"},{"key":"2159_CR22","doi-asserted-by":"crossref","unstructured":"Creswell JW, Klassen AC, Plano Clark VL, et al. Best Practices for Mixed Methods Research in the Health Sciences. Office of Behavioral and Social Sciences Research (OBSSR); 2011","DOI":"10.1037\/e566732013-001"},{"key":"2159_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19:349\u201357. https:\/\/doi.org\/10.1093\/intqhc\/mzm042.","journal-title":"Int J Qual Health Care"},{"key":"2159_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jclinepi.2019.03.008","volume":"111","author":"QN Hong","year":"2019","unstructured":"Hong QN, Pluye P, F\u00e0bregues S, et al. Improving the content validity of the mixed methods appraisal tool: a modified e-Delphi study. J Clin Epidemiol. 2019;111:49-59.e1. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.03.008.","journal-title":"J Clin Epidemiol"},{"key":"2159_CR25","doi-asserted-by":"publisher","unstructured":"Koster ES, Blom L, Philbert D, et al. The Utrecht Pharmacy Practice network for Education and Research: a network of community and hospital pharmacies in the Netherlands. Int J Clin Pharm. 2014. https:\/\/doi.org\/10.1007\/s11096-014-9954-5.","DOI":"10.1007\/s11096-014-9954-5"},{"key":"2159_CR26","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/08870440903194015","volume":"25","author":"JJ Francis","year":"2010","unstructured":"Francis JJ, Johnston M, Robertson C, et al. What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health. 2010;25:1229\u201345. https:\/\/doi.org\/10.1080\/08870440903194015.","journal-title":"Psychol Health"},{"key":"2159_CR27","doi-asserted-by":"publisher","unstructured":"Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011. https:\/\/doi.org\/10.1186\/1748-5908-6-42.","DOI":"10.1186\/1748-5908-6-42"},{"key":"2159_CR28","doi-asserted-by":"publisher","unstructured":"Watkins D, Gioia D. Mixed methods research. Oxford: Oxford University Press; 2015. https:\/\/doi.org\/10.1093\/acprof:oso\/9780199747450.001.0001.","DOI":"10.1093\/acprof:oso\/9780199747450.001.0001"},{"key":"2159_CR29","unstructured":"Utrecht University. Web Page - Institutional Review Board n.d. https:\/\/praktijkonderzoek.sites.uu.nl\/irb\/ (accessed 10 March 2025)."},{"key":"2159_CR30","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/BCP.14548","volume":"87","author":"WE van Loon","year":"2021","unstructured":"van Loon WE, Borgsteede SD, Baas GW, et al. Nature and frequency of prescription modifications in community pharmacies: a nationwide study in the Netherlands. Br J Clin Pharmacol. 2021;87:1455\u201365. https:\/\/doi.org\/10.1111\/BCP.14548.","journal-title":"Br J Clin Pharmacol"},{"key":"2159_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.thromres.2023.03.007","volume":"231","author":"SFB Van Der Horst","year":"2023","unstructured":"Van Der Horst SFB, Van Rein N, Van Mens TE, et al. Inappropriate prescriptions of direct oral anticoagulants (DOACs) in hospitalized patients: a narrative review. Thromb Res. 2023;231:135\u201340. https:\/\/doi.org\/10.1016\/j.thromres.2023.03.007.","journal-title":"Thromb Res"},{"key":"2159_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-031341","volume":"9","author":"LA Garcia Rodr\u00edguez","year":"2019","unstructured":"Garcia Rodr\u00edguez LA, Martin-Perez M, Vora P, et al. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK. BMJ Open. 2019;9:e031341. https:\/\/doi.org\/10.1136\/bmjopen-2019-031341.","journal-title":"BMJ Open"},{"key":"2159_CR33","doi-asserted-by":"publisher","unstructured":"Kefale B, Peterson GM, Mirkazemi C, et al. The effect of pharmacist-led interventions on the appropriateness and clinical outcomes of anticoagulant therapy: a systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. 2024. https:\/\/doi.org\/10.1093\/ehjqcco\/qcae045.","DOI":"10.1093\/ehjqcco\/qcae045"},{"key":"2159_CR34","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.sapharm.2023.05.009","volume":"19","author":"JF Mertens","year":"2023","unstructured":"Mertens JF, Koster ES, Deneer VHM, et al. Factors influencing pharmacists\u2019 clinical decision making in pharmacy practice. Res Social Adm Pharm. 2023;19:1267\u201377. https:\/\/doi.org\/10.1016\/j.sapharm.2023.05.009.","journal-title":"Res Social Adm Pharm"},{"key":"2159_CR35","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.sapharm.2026.01.006","volume":"22","author":"J Bolt","year":"2026","unstructured":"Bolt J, Khattra P, Chiu D, et al. Pharmacists\u2019 barriers and enablers to deprescribing: a systematic review and meta-synthesis. Res Social Adm Pharm. 2026;22:561\u201373. https:\/\/doi.org\/10.1016\/j.sapharm.2026.01.006.","journal-title":"Res Social Adm Pharm"},{"key":"2159_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s11096-025-01972-6","volume":"48","author":"J Fynn","year":"2026","unstructured":"Fynn J, Lamptey M, Coote G, et al. A mixed methods evaluation of a shared electronic health record between general practice and community pharmacy. Int J Clin Pharm. 2026;48:148\u201359. https:\/\/doi.org\/10.1007\/s11096-025-01972-6.","journal-title":"Int J Clin Pharm"},{"key":"2159_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0306033","author":"J Graafsma","year":"2024","unstructured":"Graafsma J, Klopotowska JE, Derijks HJ, et al. Adoption of antithrombotic stewardship and utilization of clinical decision support systems - a questionnaire-based survey in Dutch hospitals. PLoS ONE. 2024. https:\/\/doi.org\/10.1371\/journal.pone.0306033.","journal-title":"PLoS ONE"},{"key":"2159_CR38","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1111\/BCP.15443","volume":"88","author":"EM Donker","year":"2022","unstructured":"Donker EM, Brinkman DJ, van Rosse F, et al. Do we become better prescribers after graduation: a 1-year international follow-up study among junior doctors. Br J Clin Pharmacol. 2022;88:5218\u201326. https:\/\/doi.org\/10.1111\/BCP.15443.","journal-title":"Br J Clin Pharmacol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02159-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02159-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02159-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:58:08Z","timestamp":1789117088000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02159-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2159"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02159-3","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The questionnaire and methodology for this study was approved by the Institutional Review Board of the Division of Pharmacoepidemiology and Clinical Pharmacology (approval numbers UPF2302: February 10th, 2023, and UPF2305: April 5th, 2023).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Under Dutch law, informed consent was only required and obtained from participating pharmacists in this study, since solely anonymised and non-traceable existing patient prescription data were collected.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}